{[3-(Trifluoromethyl)phenyl]amino}carbodithioic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {[3-(Trifluoromethyl)phenyl]amino}carbodithioic acid
• 英文别名: [3-(trifluoromethyl)phenyl]carbamodithioic acid
• 化学式: C₈H₆F₃NS₂
• mdl: MFCD00175687
• 分子量: 237.27
• InChiKey: FDYQAIFKGSJGKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  45.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  {[3-(Trifluoromethyl)phenyl]amino}carbodithioic acid 在 哌啶 碳酸氢钠 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 生成 3-[(3-三氟甲基)苯基]-5-[(4-羧基苯基)亚甲基]-2-硫代-4-噻唑烷酮
  参考文献：
  名称：

  WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

  摘要：

  本文提供了高度水溶性的噻唑啉酮衍生物化合物和甘氨酸酰肼衍生物化合物，这些化合物抑制了囊性纤维化跨膜传导调节器（CFTR）的离子传输活性。本文描述的化合物和含有这些化合物的组合物对于治疗与CFTR活性异常增加相关的疾病、紊乱和疾病、紊乱和条件的后遗症非常有用，例如分泌性腹泻。这些化合物也可用于抑制或预防多囊肾病患者囊肿的扩张或形成。

  公开号：

  US20110105565A1
• 作为产物：
  描述：

  二硫化碳 、 间氨基三氟甲苯 在 三乙烯二胺 作用下， 以 甲苯 为溶剂， 生成 {[3-(Trifluoromethyl)phenyl]amino}carbodithioic acid
  参考文献：
  名称：

  二芳基硫脲衍生物作为抗癌剂的设计，合成及抗增殖活性

  摘要：

  设计并合成了两个新的含索拉非尼衍生物9a - 9t的二芳基硫脲系列产品，并评估了它们对PC-3，HCT116和MDA-MB-231细胞系的抗增殖活性。所有化合物通常对PC-3细胞均具有抗增殖活性，大多数类似物均对HCT116细胞具有有效的抗增殖活性，化合物9e，9f，9o和9p对所有这三种细胞系均具有抑制活性。所有新合成的化合物的结构均通过1 H NMR，13 C NMR和HRMS确定。

  DOI：

  10.1002/cjoc.201200708

文献信息

• Isothiocyanates from Tosyl Chloride Mediated Decomposition of in Situ Generated Dithiocarbamic Acid Salts
  作者：Rince Wong、Sarah J. Dolman

  DOI：10.1021/jo070246n

  日期：2007.5.1

  A facile and general protocol for the preparation of isothiocyanates from alkyl and aryl amines is reported. This method relies on a tosyl chloride mediated decomposition of a dithiocarbamate salt that is generated in situ by treatment of an amine with carbon disulfide and triethylamine. Utilizing this protocol, we have prepared 19-alkyl- and arylisothiocyanates in moderate to excellent yield.

  据报道，由烷基胺和芳基胺制备异硫氰酸酯的简便通用方法。该方法依赖于甲苯磺酰氯介导的二硫代氨基甲酸盐的分解，该二硫代氨基甲酸盐是通过用二硫化碳和三乙胺处理胺而原位产生的。利用该方案，我们以中等至极好的收率制备了19-烷基异硫氰酸酯和芳基异硫氰酸酯。
• Design, Synthesis and Antiproliferative Activities of Diaryl Thiourea Derivatives as Anticancer Agents
  作者：Jianwen Yao、Zuopeng He、Jing Chen、Daquan Chen、Wei Sun、Wenfang Xu

  DOI：10.1002/cjoc.201200708

  日期：2012.10

  Two new series of diaryl thiourea containing sorafenib derivatives 9a–9t were designed and synthesized, and their antiproliferative activities against PC‐3, HCT116 and MDA‐MB‐231 cell lines were evaluated. All compounds generally showed antiproliferative activity to PC‐3 cells, most of the analogs exhibited potent antiproliferative activity to HCT116 cells, and compounds 9e, 9f, 9o and 9p demonstrated

  设计并合成了两个新的含索拉非尼衍生物9a - 9t的二芳基硫脲系列产品，并评估了它们对PC-3，HCT116和MDA-MB-231细胞系的抗增殖活性。所有化合物通常对PC-3细胞均具有抗增殖活性，大多数类似物均对HCT116细胞具有有效的抗增殖活性，化合物9e，9f，9o和9p对所有这三种细胞系均具有抑制活性。所有新合成的化合物的结构均通过1 H NMR，13 C NMR和HRMS确定。
• Thiourea and thioether derivatives of sorafenib: synthesis, crystal structure, and antiproliferative activity
  作者：Jianwen Yao、Jing Chen、Zuopeng He、Wei Sun、Hao Fang、Wenfang Xu

  DOI：10.1007/s00044-012-0400-8

  日期：2013.8

  A series of novel sorafenib derivatives containing diaryl thiourea and thioether, 9a-u, was designed and synthesized, and their antiproliferative activities against HCT116 and MDA-MB-231 cell lines were also evaluated and described. Most compounds exhibited potent antiproliferative activity against HCT116 cells with IC50 = 1.8-80.4 mu M. Compounds 9p, 9r, and 9s demonstrated competitive antiproliferative activities to sorafenib, against all two cancer cell lines. The structures of all the newly synthesized compounds were determined by H-1 NMR, C-13 NMR, and HRMS, and compound 9n was characterized by single-crystal X-ray diffraction. Primary structure-activity relationships (SAR) have also been established.
• Design, synthesis and biological activities of sorafenib derivatives as antitumor agents
  作者：Jianwen Yao、Zuopeng He、Jing Chen、Wei Sun、Hao Fang、Wenfang Xu

  DOI：10.1016/j.bmcl.2012.09.031

  日期：2012.11

  A series of novel sorafenib derivatives, 9a-w, was designed and synthesized in high yields using various substituted anilines, and their antiproliferative activities against HCT116, PC-3 and MDA-MB-231 cell lines were also evaluated and described. All compounds exhibited potent antiproliferative activity against HCT116 and PC-3 cells with IC50 = 2.8-52.0 and 2.2-45.6 mu M; compounds 9p and 9q demonstrated competitive antiproliferative activities to sorafenib against all three cancer cell lines, the cytotoxicity of compound 9r is more potent than that of sorafenib. Compounds (9g, 9p, 9q and 9r) were chosen for further evaluation of the anti-angiogenesis activity, and showed the inhibition of sprout formation from aortic ring ex vivo. The structures of all the newly synthesized compounds were determined by H-1 NMR, C-13 NMR and HRMS. (C) 2012 Elsevier Ltd. All rights reserved.
• Thiazolidinone CFTR inhibitors with improved water solubility identified by structure–activity analysis
  作者：N.D. Sonawane、A.S. Verkman

  DOI：10.1016/j.bmc.2008.07.044

  日期：2008.9

  The thiazolidinone 3-[(3-trifluoromethyl)phenyl]-5-[(4-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone (CFTRinh-172) inhibits cystic fibrosis transmembrane conductance regulator ( CFTR) chloride channel conductance with submicromolar affinity and blocks cholera toxin-induced intestinal fluid secretion. Fifty-eight CFTRinh-172 analogs were synthesized to identify CFTR inhibitors with improved water solubility, exploring modi. cations in its two phenyl rings, thiazolidinone core, and core-phenyl connectors. Greatest CFTR inhibition potency was found for 3-CF3 and polar group-substituted-phenyl rings, and a thiazolidinone core. Two compounds with similar to 1 mu M CFTR inhibition potency and solubility >180 mu M(>10-fold more than CFTRinh-172) were identified: Tetrazolo-172, containing 4-tetrazolophenyl in place of 4-carboxyphenyl, and Oxo-172, containing thiazolidinedione in place of the thiazolidinone core. These water soluble thiazolidinone analogs had low cellular toxicity. The improved water solubility of Tetrazolo- and Oxo-172 make them potential lead candidates for therapy of secretory diarrheas and polycystic kidney disease. (C) 2008 Elsevier Ltd. All rights reserved.